Table 3.
Inhibition of prostate cancer cell viability by AR antagonists
| Compound | VCaP | LAPC‐4 | LNCaP |
|---|---|---|---|
| Darolutamide | 410 ± 150 | 500 ± 220 | 5,260 ± 2,510 |
| (S,R)‐darolutamide | 250 ± 60 | 440 ± 110 | 4,710 ± 1,010 |
| (S,S)‐darolutamide | 380 ± 90 | 840 ± 350 | 5,230 ± 1,940 |
| Keto‐darolutamide | 500 ± 140 | 660 ± 170 | 3,210 ± 1,010 |
| Enzalutamide | 440 ± 130 | 680 ± 460 | 770 ± 3602 |
| Apalutamide | 390 ± 130 | 1,100 ± 6001 | 5,900 ± 2,560 |
| Bicalutamide | 4,950 ± 1,8401 | 1,300 ± 7701 | 3,470 ± 2,4502 |
Notes: Mean IC50 ± SD values from at least five biological replicates are given in nM. Cells were stimulated with 0.1 nM (VCaP), 10 nM (LAPC‐4) or 1 nM (LNCaP) R1881. Statistical analysis was performed with t‐test on average pIC50 values. Superscripts indicate inhibitory activity that is significantly lower1 or higher2 compared to the corresponding darolutamide value.